FAM13A-AS1: A promising drug target and biomarker for cancer (G285512)

Target Name: FAM13A-AS1

NCBI ID: G285512

FAM13A-AS1

Other Name(s): NCRNA00039 | FAM13AOS | FAM13A antisense RNA 1 | FAM13A1OS

FAM13A-AS1: A promising drug target and biomarker for cancer

FAM13A-AS1, a gene located on chromosome 13q22.1, has been identified as a potential drug target and biomarker for cancer. This gene has been implicated in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancers. The FAM13A-AS1 gene has also been associated with the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

Drug targeting FAM13A-AS1

FAM13A-AS1 is a gene that has been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and angiogenesis. Several studies have suggested that inhibiting the activity of FAM13A-AS1 may be a promising strategy for cancer treatment.

One potential mechanism by which FAM13A-AS1 could be targeted is through its role in the regulation of the Notch signaling pathway. Notch signaling is a process that involves the interaction between Notch proteins and their ligands, which can induce the activation of various cellular processes, including cell proliferation and survival.

Several studies have suggested that FAM13A-AS1 may be a negative regulator of the Notch signaling pathway. This is because the FAM13A-AS1 gene has been shown to encode a protein that is capable of binding to the Notch receptor, a protein that is involved in the Notch signaling pathway.

In addition to its role in the Notch signaling pathway, FAM13A-AS1 has also been shown to be involved in the regulation of other cellular processes, including cell adhesion and migration. These functions are important for the development and progression of cancer, as they allow cells to migrate and invade new territories.

Biomarker potential

FAM13A-AS1 has also been suggested as a potential biomarker for cancer. This is because the gene has been shown to be expressed in various types of cancer cells, including those from breast, ovarian, and colorectal cancers. Additionally, the FAM13A-AS1 gene has been shown to be involved in the regulation of cellular processes that are important for cancer development, such as cell adhesion and migration.

FAM13A-AS1 has also been shown to be involved in the regulation of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. These conditions are characterized by the progressive loss of brain cells, which can lead to a range of symptoms, including cognitive decline and behavior changes.

Conclusion

In conclusion, FAM13A-AS1 is a gene that has been implicated in the development and progression of various types of cancer, as well as neurodegenerative diseases. The FAM13A-AS1 gene has also been shown to be involved in the regulation of various cellular processes that are important for cancer development, including cell adhesion, migration, and the Notch signaling pathway.

Further research is needed to fully understand the role of FAM13A-AS1 in cancer and other diseases. However, the potential implications of targeting this gene with drugs or other therapeutic agents are significant. As more research is done, it is likely that the FAM13A-AS1 gene will be identified as a promising drug target and biomarker for cancer.

Protein Name: FAM13A Antisense RNA 1

The "FAM13A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM13A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets